Form 4: Celldex Therapeutics Executive Exercises Options and Sells Shares
SEC Form 4 Filing
Margo Heath-Chiozzi, SVP of Regulatory Affairs at Celldex Therapeutics, exercised stock options and sold shares on June 3, 2024.
Summary
- On June 3, 2024, Margo Heath-Chiozzi, SVP of Regulatory Affairs at Celldex Therapeutics, exercised incentive stock options to acquire 6,289 shares at $9.0165 and 58,369 shares at $10.38.
- She then sold 58,369 shares at a weighted average price of $33.6495, with prices ranging from $33.27 to $34.08.
- Following these transactions, Heath-Chiozzi directly owns 13,383 shares of Celldex Therapeutics common stock and 23,023 derivative securities.
Sentiment
Score: 5
Explanation: This is a neutral disclosure of insider trading activity. The sentiment is neither particularly positive nor negative as it simply reflects the execution of stock options and subsequent sale of shares.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors often monitor these filings for signals about management's confidence in the company's future prospects.
Stakeholder Impact
- The sale of shares by an executive could be perceived negatively by some shareholders, but it is a common practice and doesn't necessarily indicate a lack of confidence in the company.
Key Dates
| Date | Description |
|---|---|
| 06/13/2022 | Option for 6,289 shares fully vested |
| 06/18/2021 | 25% of option for 58,369 shares vested, remainder vests quarterly over 12 quarters |
| 06/03/2024 | Earliest transaction date: Exercise of stock options and sale of shares |
| 06/05/2024 | Date of signature for the Form 4 filing |
| 06/13/2028 | Expiration date for incentive stock option (Right to Buy) at $9.0165 |
| 06/18/2030 | Expiration date for incentive stock option (Right to Buy) at $10.38 |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.